医学
重症监护医学
疾病
静脉血栓栓塞
抗凝剂
肾脏疾病
血栓形成
直接凝血酶抑制剂的发现与发展
外科
内科学
凝血酶
血小板
作者
Davide Santagata,Paolo Prandoni,Walter Ageno
出处
期刊:Blood Reviews
[Elsevier]
日期:2023-11-01
卷期号:62: 101119-101119
被引量:4
标识
DOI:10.1016/j.blre.2023.101119
摘要
Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs effectively reduce the rates of thrombotic events, they simultaneously increase the risk of bleeding. Moreover, their risk-to-benefit balance is problematic in some patients, such as those with severe chronic kidney disease or those at high bleeding risk. A novel anticoagulation method, FXI inhibition has emerged as a promising alternative. It demonstrates a strong rationale for the prevention and treatment of venous thromboembolism and the potential fulfillment of unmet clinical needs in the cardiovascular field. A number of FXI inhibitors are currently undergoing clinical investigation. The objective of this review is to provide an overview of early results of research on FXI inhibitors in the cardiovascular setting, offering valuable insights into their potential role in shaping the future of anticoagulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI